A long-term surviving patient with recurrent low-grade serous ovarian carcinoma treated with the MEK1/2 inhibitor, selumetinib

BACKGROUND: Selumetinib is a potent, selective, orally available, and non-ATP competitive small molecule inhibitor of mitogen-activated protein kinase kinase 1/2 (MEK1/2) that has demonstrated single agent activity in a number of solid tumor including recurrent low-grade serous ovarian carcinoma (LG...

Descripción completa

Detalles Bibliográficos
Autores principales: Takekuma, Munetaka, Wong, Kwong K., Coleman, Robert L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4880811/
https://www.ncbi.nlm.nih.gov/pubmed/27231576
http://dx.doi.org/10.1186/s40661-016-0026-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4880811/
https://www.ncbi.nlm.nih.gov/pubmed/27231576
http://dx.doi.org/10.1186/s40661-016-0026-5

Ejemplares similares